Influenza, flu, season is coming and you want to prepare yourself physically and mentally. Learn what you need to do so that you do not get the flu this year.
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia.
“We are pleased to receive this prestigious honor, and thankful to our partners, Families Fighting Flu and several collegiate student organizations, for their dedication to spreading the word about the dangers of flu and encouraging their peers to get vaccinated,” said Dr. Marie Mazur, Vice President of Global Commercial Development and Policy. “Moving forward, Seqirus is committed to building on this season’s success with college students and continuing the important work of flu prevention for all.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7833751-seqirus-national-award-knockoutflu/
AstraZeneca announced today that it has collaborated with actor and father James Van Der Beek on a campaign to dispel common myths about the flu and underscore the importance of annual influenza vaccination for eligible individuals and families. As part of the campaign, Van Der Beek stars in an informative and comedic video, called “Just the Flu Facts,” in which he uses his signature sense of humor to debunk common misconceptions about seasonal influenza that are often barriers to vaccination.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7312451-medimmune-specialty-care-james-van-der-beek-flumist-quadrivalent-encourage-flu-shot/
Today, MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced it has joined with actress Tia Mowry to raise awareness about the importance of an annual flu vaccination. To kick-off the campaign, MedImmune Specialty Care and Mowry unveiled an online video, “I Insist!” (www.YouTube.com/InsistOnTheMist), which uses comedy to educate busy families about the importance of living a healthy lifestyle and making flu vaccination a priority. For Mowry, this includes vaccination with FluMistQuadrivalent, the first and only FDA-approved needle-free flu vaccine for eligible persons 2-49 years old. FluMist Quadrivalent is administered as a gentle mist sprayed into the nose, where the influenza virus usually enters the body.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63079-medimmune-specialty-care-tia-mowry-flumist-quadrivalent-encourage-flu-shot
Building upon its efforts to provide greater access to vaccines and other health care services for populations in need, Walgreens (NYSE: WAG) (Nasdaq: WAG) is partnering with the United Nations Foundation this flu season, to help provide up to 3 million life-saving vaccines to children in developing countries through a donation to the Foundation’s Shot@Life campaign.
To view Multimedia News Release, go to http://www.multivu.com/players/English/62923-walgreens-flu-season2013
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
During flu season, when fever, aches, and chills hit, it is easy to forget one’s manners. A recent survey of more than 1,000 Americans found that nearly two-thirds (64%) of those who had influenza in the past three years admit to being “That Guy,” who despite experiencing flu symptoms, continues to go about his/her daily activities.
As part of its “Are You That Guy?” influenza education campaign, the National Foundation for Infectious Diseases (NFID) is partnering with the Emily Post Institute to remind Americans to do the responsible thing during flu season and practice behavior that will help limit the spread of influenza, a highly contagious virus. The campaign also reminds Americans to see a doctor quickly if flu strikes. The campaign offers flu etiquette tips for managing common situations where the flu virus might be shared from one person to another, such as shaking hands during a business meeting, over a family dinner, or when faced with a fellow airplane traveler who is showing signs of flu.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53536-nfid-emily-post-institute-educate-about-spreading-manners-not-influenza
During flu season, when fever, aches, and chills hit, it is easy to forget one’s manners. A recent survey of more than 1,000 Americans found that nearly two-thirds (64%) of those who had influenza in the past three years admit to being “That Guy,” who despite experiencing flu symptoms, continues to go about his/her daily activities.
As part of its “Are You That Guy?” influenza education campaign, the National Foundation for Infectious Diseases (NFID) is partnering with the Emily Post Institute to remind Americans to do the responsible thing during flu season and practice behavior that will help limit the spread of influenza, a highly contagious virus. The campaign also reminds Americans to see a doctor quickly if flu strikes. The campaign offers flu etiquette tips for managing common situations where the flu virus might be shared from one person to another, such as shaking hands during a business meeting, over a family dinner, or when faced with a fellow airplane traveler who is showing signs of flu.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53536-nfid-emily-post-institute-educate-about-spreading-manners-not-influenza
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
